Pure Immature Teratoma of the Ovary in Adults Thirty-Year Experience of a Single Tertiary Care Center

被引:33
作者
Alwazzan, Ahmad Bakr [1 ,2 ,3 ]
Popowich, Shaundra [1 ,2 ]
Dean, Erin [1 ,2 ]
Robinson, Christine [1 ,2 ]
Lotocki, Robert [1 ,2 ]
Altman, Alon D. [1 ,2 ]
机构
[1] Univ Manitoba, Winnipeg Hlth Sci Ctr, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Winnipeg, MB, Canada
[2] Univ Manitoba, CancerCare Manitoba, Winnipeg, MB, Canada
[3] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Jeddah 21413, Saudi Arabia
关键词
Pure immature teratoma of the ovary; Vincristine; actinomycin D; cyclophosphamide; Etoposide; cisplatin; GERM-CELL TUMORS; CISPLATIN-BASED CHEMOTHERAPY; GYNECOLOGIC-ONCOLOGY-GROUP; STAGE-I; ALPHA-FETOPROTEIN; FERTILITY PRESERVATION; ADJUVANT CHEMOTHERAPY; REPRODUCTIVE FUNCTION; CONSERVATIVE SURGERY; SURVEILLANCE POLICY;
D O I
10.1097/IGC.0000000000000541
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The aim of this study was to evaluate clinicopathologic characteristics, treatment outcome, and reproductive function in women diagnosed with ovarian immature teratoma (IT). Our standard chemotherapy regime is currently etoposide/cisplatin (EP), creating a unique opportunity to evaluate this protocol in ovarian ITs. Materials and Methods This study is a retrospective analysis. Twenty-seven women older than 18 years with ovarian IT stages IA to IIIC were identified and included in this study. Patients were treated at 1 institution, Health Sciences Center, Women's Hospital, Winnipeg, Manitoba, Canada, between 1983 and 2013. Results The median age at diagnosis was 27.0 years (range, 18-36 years). Twenty-two (82%) presented with an International Federation of Gynecology and Obstetrics stage I disease, 3 (11%) had stage II, and 2 patients (7%) had stage III disease. The histologic grade distribution was grade I in 9 patients (33%), grade II in 3 patients (11%), and grade III in 15 patients (56%). Initial management was surgical for all patients: 3 (11%) hysterectomy and bilateral salpingo-oophorectomy, 1 (4%) cystectomy only, and 23 (85%) unilateral salpingo-oophorectomy. Twenty-one patients (78%) received adjuvant therapy. The median follow-up was 60 months (range, 36-72 months). One patient recurred (histological grade III) 6 months after surgery and had a complete clinical response to 4 cycles of EP chemotherapy. Twelve patients reported an attempt to conceive resulting in 10 pregnancies (8 after chemotherapy). Conclusions Ovarian IT is a curable disease. Fertility-sparing surgery should be offered. Adjuvant treatment with cisplatinum-based chemotherapy, typically with bleomycin, etoposide, and cisplatin, is still considered the standard in stages greater than stage IA grade I. Etoposide/cisplatin as a primary chemotherapy regime for early- or advanced-stage disease is an effective treatment with minimal adverse effects and high tolerability. This is the first published study examining EP as a primary treatment modality for IT. Further studies are needed to strengthen these findings.
引用
收藏
页码:1616 / 1622
页数:7
相关论文
共 47 条
[11]  
2-L
[12]   Management of ovarian germ cell tumors [J].
Gershenson, David M. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) :2938-2943
[14]  
Ikarashi T, 1984, Asia Oceania J Obstet Gynaecol, V10, P523
[15]   Treatment of malignant ovarian germ cell tumors with preservation of fertility - Reproductive performance after persistent remission [J].
Kanazawa, K ;
Suzuki, T ;
Sakumoto, K .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (03) :244-248
[16]   IMMATURE TERATOMA OF THE OVARY [J].
KAWAI, M ;
KANO, T ;
FURUHASHI, Y ;
IWATA, M ;
NAKASHIMA, N ;
IMAI, N ;
KUZUYA, K ;
HAYASHI, H ;
OHTA, M ;
ARII, Y ;
TOMODA, Y .
GYNECOLOGIC ONCOLOGY, 1991, 40 (02) :133-137
[17]   Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors [J].
Kondagunta, GV ;
Bacik, J ;
Bajorin, D ;
Dobrzynski, D ;
Sheinfeld, J ;
Motzer, RJ ;
Bosl, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9290-9294
[18]   IMMATURE TERATOMA OF THE OVARY [J].
KOULOS, JP ;
HOFFMAN, JS ;
STEINHOFF, MM .
GYNECOLOGIC ONCOLOGY, 1989, 34 (01) :46-49
[19]  
LAWSON CS, 1989, CANCER-AM CANCER SOC, V63, P804, DOI 10.1002/1097-0142(19890215)63:4<804::AID-CNCR2820630433>3.0.CO
[20]  
2-N